JP2007529426A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007529426A5 JP2007529426A5 JP2007503101A JP2007503101A JP2007529426A5 JP 2007529426 A5 JP2007529426 A5 JP 2007529426A5 JP 2007503101 A JP2007503101 A JP 2007503101A JP 2007503101 A JP2007503101 A JP 2007503101A JP 2007529426 A5 JP2007529426 A5 JP 2007529426A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- disease
- och
- alkyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 62
- 241001465754 Metazoa Species 0.000 claims 44
- 206010028980 Neoplasm Diseases 0.000 claims 42
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 37
- 201000010099 disease Diseases 0.000 claims 35
- 238000000034 method Methods 0.000 claims 32
- 125000000217 alkyl group Chemical group 0.000 claims 24
- 125000000753 cycloalkyl group Chemical group 0.000 claims 24
- 230000033115 angiogenesis Effects 0.000 claims 21
- 208000015181 infectious disease Diseases 0.000 claims 19
- 230000001684 chronic effect Effects 0.000 claims 18
- 230000001419 dependent effect Effects 0.000 claims 15
- 241000282412 Homo Species 0.000 claims 13
- 201000011510 cancer Diseases 0.000 claims 13
- 208000025865 Ulcer Diseases 0.000 claims 12
- 206010023332 keratitis Diseases 0.000 claims 12
- 239000000126 substance Substances 0.000 claims 12
- 231100000397 ulcer Toxicity 0.000 claims 12
- 239000003814 drug Substances 0.000 claims 10
- 238000004519 manufacturing process Methods 0.000 claims 10
- 239000008280 blood Substances 0.000 claims 9
- 210000004369 blood Anatomy 0.000 claims 9
- 230000002159 abnormal effect Effects 0.000 claims 8
- 208000032839 leukemia Diseases 0.000 claims 8
- 230000002757 inflammatory effect Effects 0.000 claims 7
- 230000001404 mediated effect Effects 0.000 claims 7
- 206010005003 Bladder cancer Diseases 0.000 claims 6
- 208000007514 Herpes zoster Diseases 0.000 claims 6
- 208000034578 Multiple myelomas Diseases 0.000 claims 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 6
- 206010038910 Retinitis Diseases 0.000 claims 6
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 6
- 230000001154 acute effect Effects 0.000 claims 6
- -1 bacteriostatic Substances 0.000 claims 6
- 210000001185 bone marrow Anatomy 0.000 claims 6
- 230000007850 degeneration Effects 0.000 claims 6
- 201000011066 hemangioma Diseases 0.000 claims 6
- 208000002780 macular degeneration Diseases 0.000 claims 6
- 230000001613 neoplastic effect Effects 0.000 claims 6
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 6
- 201000005112 urinary bladder cancer Diseases 0.000 claims 6
- 208000019838 Blood disease Diseases 0.000 claims 5
- 201000009273 Endometriosis Diseases 0.000 claims 5
- 208000014951 hematologic disease Diseases 0.000 claims 5
- 208000018706 hematopoietic system disease Diseases 0.000 claims 5
- 230000001225 therapeutic effect Effects 0.000 claims 5
- 208000019553 vascular disease Diseases 0.000 claims 5
- 208000030507 AIDS Diseases 0.000 claims 4
- 208000002874 Acne Vulgaris Diseases 0.000 claims 4
- 206010001257 Adenoviral conjunctivitis Diseases 0.000 claims 4
- 208000031104 Arterial Occlusive disease Diseases 0.000 claims 4
- 201000001320 Atherosclerosis Diseases 0.000 claims 4
- 206010003645 Atopy Diseases 0.000 claims 4
- 206010044583 Bartonella Infections Diseases 0.000 claims 4
- 208000009137 Behcet syndrome Diseases 0.000 claims 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 208000026310 Breast neoplasm Diseases 0.000 claims 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims 4
- 208000009043 Chemical Burns Diseases 0.000 claims 4
- 208000002691 Choroiditis Diseases 0.000 claims 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims 4
- 206010009944 Colon cancer Diseases 0.000 claims 4
- 208000011231 Crohn disease Diseases 0.000 claims 4
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 4
- 208000019878 Eales disease Diseases 0.000 claims 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 4
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 4
- 208000010412 Glaucoma Diseases 0.000 claims 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 4
- 208000009889 Herpes Simplex Diseases 0.000 claims 4
- 208000017604 Hodgkin disease Diseases 0.000 claims 4
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 4
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 4
- 206010051151 Hyperviscosity syndrome Diseases 0.000 claims 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 4
- 206010062038 Lip neoplasm Diseases 0.000 claims 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 4
- 208000016604 Lyme disease Diseases 0.000 claims 4
- 206010025323 Lymphomas Diseases 0.000 claims 4
- 208000032271 Malignant tumor of penis Diseases 0.000 claims 4
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 4
- 206010062207 Mycobacterial infection Diseases 0.000 claims 4
- 206010029260 Neuroblastoma Diseases 0.000 claims 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 4
- 206010033128 Ovarian cancer Diseases 0.000 claims 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 4
- 208000000821 Parathyroid Neoplasms Diseases 0.000 claims 4
- 206010034277 Pemphigoid Diseases 0.000 claims 4
- 208000002471 Penile Neoplasms Diseases 0.000 claims 4
- 206010034299 Penile cancer Diseases 0.000 claims 4
- 208000003971 Posterior uveitis Diseases 0.000 claims 4
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 claims 4
- 206010060862 Prostate cancer Diseases 0.000 claims 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 4
- 201000004681 Psoriasis Diseases 0.000 claims 4
- 201000002154 Pterygium Diseases 0.000 claims 4
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 4
- 206010038389 Renal cancer Diseases 0.000 claims 4
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 4
- 206010038848 Retinal detachment Diseases 0.000 claims 4
- 201000000582 Retinoblastoma Diseases 0.000 claims 4
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims 4
- 206010038934 Retinopathy proliferative Diseases 0.000 claims 4
- 241001303601 Rosacea Species 0.000 claims 4
- 206010039705 Scleritis Diseases 0.000 claims 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 4
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 4
- 206010057644 Testis cancer Diseases 0.000 claims 4
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 4
- 201000005485 Toxoplasmosis Diseases 0.000 claims 4
- 206010052779 Transplant rejections Diseases 0.000 claims 4
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 4
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 4
- 206010046851 Uveitis Diseases 0.000 claims 4
- 206010058990 Venous occlusion Diseases 0.000 claims 4
- 208000014070 Vestibular schwannoma Diseases 0.000 claims 4
- 206010047663 Vitritis Diseases 0.000 claims 4
- 206010000496 acne Diseases 0.000 claims 4
- 208000004064 acoustic neuroma Diseases 0.000 claims 4
- 208000021328 arterial occlusion Diseases 0.000 claims 4
- 206010003246 arthritis Diseases 0.000 claims 4
- 230000001580 bacterial effect Effects 0.000 claims 4
- 206010004145 bartonellosis Diseases 0.000 claims 4
- 201000010881 cervical cancer Diseases 0.000 claims 4
- 208000029742 colonic neoplasm Diseases 0.000 claims 4
- 208000030381 cutaneous melanoma Diseases 0.000 claims 4
- 208000021373 epidemic keratoconjunctivitis Diseases 0.000 claims 4
- 201000004101 esophageal cancer Diseases 0.000 claims 4
- 230000002538 fungal effect Effects 0.000 claims 4
- 206010017758 gastric cancer Diseases 0.000 claims 4
- 230000012010 growth Effects 0.000 claims 4
- 208000013653 hyalitis Diseases 0.000 claims 4
- 201000001371 inclusion conjunctivitis Diseases 0.000 claims 4
- 201000010982 kidney cancer Diseases 0.000 claims 4
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 4
- 201000006721 lip cancer Diseases 0.000 claims 4
- 201000007270 liver cancer Diseases 0.000 claims 4
- 208000014018 liver neoplasm Diseases 0.000 claims 4
- 201000005202 lung cancer Diseases 0.000 claims 4
- 208000020816 lung neoplasm Diseases 0.000 claims 4
- 206010025135 lupus erythematosus Diseases 0.000 claims 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 4
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 claims 4
- 201000001441 melanoma Diseases 0.000 claims 4
- 208000027531 mycobacterial infectious disease Diseases 0.000 claims 4
- 208000001491 myopia Diseases 0.000 claims 4
- 230000004379 myopia Effects 0.000 claims 4
- 201000003142 neovascular glaucoma Diseases 0.000 claims 4
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 claims 4
- 201000008482 osteoarthritis Diseases 0.000 claims 4
- 201000008968 osteosarcoma Diseases 0.000 claims 4
- 201000002528 pancreatic cancer Diseases 0.000 claims 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 4
- 230000006785 proliferative vitreoretinopathy Effects 0.000 claims 4
- 206010038038 rectal cancer Diseases 0.000 claims 4
- 201000001275 rectum cancer Diseases 0.000 claims 4
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 4
- 230000004264 retinal detachment Effects 0.000 claims 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 4
- 201000004700 rosacea Diseases 0.000 claims 4
- 201000000306 sarcoidosis Diseases 0.000 claims 4
- 201000006476 shipyard eye Diseases 0.000 claims 4
- 208000007056 sickle cell anemia Diseases 0.000 claims 4
- 201000000849 skin cancer Diseases 0.000 claims 4
- 201000003708 skin melanoma Diseases 0.000 claims 4
- 201000002314 small intestine cancer Diseases 0.000 claims 4
- 201000011549 stomach cancer Diseases 0.000 claims 4
- 208000011580 syndromic disease Diseases 0.000 claims 4
- 208000006379 syphilis Diseases 0.000 claims 4
- 230000009885 systemic effect Effects 0.000 claims 4
- 201000003120 testicular cancer Diseases 0.000 claims 4
- 201000002510 thyroid cancer Diseases 0.000 claims 4
- 210000001519 tissue Anatomy 0.000 claims 4
- 206010044325 trachoma Diseases 0.000 claims 4
- 206010046766 uterine cancer Diseases 0.000 claims 4
- 230000029663 wound healing Effects 0.000 claims 4
- 208000037663 Best vitelliform macular dystrophy Diseases 0.000 claims 3
- 208000031953 Hereditary hemorrhagic telangiectasia Diseases 0.000 claims 3
- 206010029113 Neovascularisation Diseases 0.000 claims 3
- 201000004404 Neurofibroma Diseases 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 201000007790 vitelliform macular dystrophy Diseases 0.000 claims 3
- 208000020938 vitelliform macular dystrophy 2 Diseases 0.000 claims 3
- 206010000050 Abdominal adhesions Diseases 0.000 claims 2
- 201000000736 Amenorrhea Diseases 0.000 claims 2
- 206010001928 Amenorrhoea Diseases 0.000 claims 2
- 208000035143 Bacterial infection Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 206010048964 Carotid artery occlusion Diseases 0.000 claims 2
- 108010010803 Gelatin Proteins 0.000 claims 2
- 206010018691 Granuloma Diseases 0.000 claims 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 2
- 241000228402 Histoplasma Species 0.000 claims 2
- 201000002563 Histoplasmosis Diseases 0.000 claims 2
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 2
- 208000002260 Keloid Diseases 0.000 claims 2
- 206010027304 Menopausal symptoms Diseases 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 208000028606 Optic disc pit Diseases 0.000 claims 2
- 208000010191 Osteitis Deformans Diseases 0.000 claims 2
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- 208000027868 Paget disease Diseases 0.000 claims 2
- 208000010362 Protozoan Infections Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 206010039710 Scleroderma Diseases 0.000 claims 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 2
- 208000027073 Stargardt disease Diseases 0.000 claims 2
- 206010042674 Swelling Diseases 0.000 claims 2
- 206010047141 Vasodilatation Diseases 0.000 claims 2
- 208000010011 Vitamin A Deficiency Diseases 0.000 claims 2
- 206010052428 Wound Diseases 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 2
- 230000000996 additive effect Effects 0.000 claims 2
- 239000000443 aerosol Substances 0.000 claims 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims 2
- 231100000540 amenorrhea Toxicity 0.000 claims 2
- 208000007502 anemia Diseases 0.000 claims 2
- 239000003963 antioxidant agent Substances 0.000 claims 2
- 230000003078 antioxidant effect Effects 0.000 claims 2
- 235000006708 antioxidants Nutrition 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims 2
- 230000003385 bacteriostatic effect Effects 0.000 claims 2
- 239000011230 binding agent Substances 0.000 claims 2
- 229920002988 biodegradable polymer Polymers 0.000 claims 2
- 239000004621 biodegradable polymer Substances 0.000 claims 2
- 208000015294 blood coagulation disease Diseases 0.000 claims 2
- 210000004204 blood vessel Anatomy 0.000 claims 2
- 208000015322 bone marrow disease Diseases 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 208000037976 chronic inflammation Diseases 0.000 claims 2
- 230000006020 chronic inflammation Effects 0.000 claims 2
- 239000006071 cream Substances 0.000 claims 2
- 239000002270 dispersing agent Substances 0.000 claims 2
- 230000032692 embryo implantation Effects 0.000 claims 2
- 239000000839 emulsion Substances 0.000 claims 2
- 239000000796 flavoring agent Substances 0.000 claims 2
- 239000006260 foam Substances 0.000 claims 2
- 235000013355 food flavoring agent Nutrition 0.000 claims 2
- 239000000499 gel Substances 0.000 claims 2
- 239000008273 gelatin Substances 0.000 claims 2
- 229920000159 gelatin Polymers 0.000 claims 2
- 235000019322 gelatine Nutrition 0.000 claims 2
- 235000011852 gelatine desserts Nutrition 0.000 claims 2
- 235000011187 glycerol Nutrition 0.000 claims 2
- 239000008187 granular material Substances 0.000 claims 2
- 238000005469 granulation Methods 0.000 claims 2
- 230000003179 granulation Effects 0.000 claims 2
- 230000002008 hemorrhagic effect Effects 0.000 claims 2
- 239000003701 inert diluent Substances 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 238000007918 intramuscular administration Methods 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 210000001117 keloid Anatomy 0.000 claims 2
- 230000035984 keratolysis Effects 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 239000007937 lozenge Substances 0.000 claims 2
- 239000000314 lubricant Substances 0.000 claims 2
- 210000001165 lymph node Anatomy 0.000 claims 2
- 208000027202 mammary Paget disease Diseases 0.000 claims 2
- 230000005906 menstruation Effects 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000002324 mouth wash Substances 0.000 claims 2
- 229940051866 mouthwash Drugs 0.000 claims 2
- 230000002107 myocardial effect Effects 0.000 claims 2
- 230000009826 neoplastic cell growth Effects 0.000 claims 2
- 239000002674 ointment Substances 0.000 claims 2
- 230000016087 ovulation Effects 0.000 claims 2
- 239000006072 paste Substances 0.000 claims 2
- 235000010603 pastilles Nutrition 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000843 powder Substances 0.000 claims 2
- 239000003755 preservative agent Substances 0.000 claims 2
- 230000002335 preservative effect Effects 0.000 claims 2
- 208000028172 protozoa infectious disease Diseases 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- 210000000952 spleen Anatomy 0.000 claims 2
- 239000007921 spray Substances 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 239000000829 suppository Substances 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- 239000000375 suspending agent Substances 0.000 claims 2
- 239000000725 suspension Substances 0.000 claims 2
- 230000008961 swelling Effects 0.000 claims 2
- 239000003826 tablet Substances 0.000 claims 2
- 239000002562 thickening agent Substances 0.000 claims 2
- 230000000699 topical effect Effects 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- 239000006216 vaginal suppository Substances 0.000 claims 2
- 229940120293 vaginal suppository Drugs 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- 230000006492 vascular dysfunction Effects 0.000 claims 2
- 230000024883 vasodilation Effects 0.000 claims 2
- 238000009423 ventilation Methods 0.000 claims 2
- 230000003519 ventilatory effect Effects 0.000 claims 2
- 206010023330 Keloid scar Diseases 0.000 claims 1
- 230000002491 angiogenic effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000004177 elastic tissue Anatomy 0.000 claims 1
- 210000004126 nerve fiber Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 0 C[C@@](*CC1)(C1C1CCc2c3)C=CC1c2cc(*=I)c3C(N)=O Chemical compound C[C@@](*CC1)(C1C1CCc2c3)C=CC1c2cc(*=I)c3C(N)=O 0.000 description 5
- YQJWOUQGXATDAE-CBTMWXCYSA-N C[C@@]1(CC2)C=CCC1C(CCc1c3)C2c1cc(OC)c3C(N)=O Chemical compound C[C@@]1(CC2)C=CCC1C(CCc1c3)C2c1cc(OC)c3C(N)=O YQJWOUQGXATDAE-CBTMWXCYSA-N 0.000 description 1
- UFLIUMJUCSZFHG-NZWIDFBWSA-N C[C@@]1(CC2)C=CCC1C(CCc1c3)C2c1cc([RnH])c3C(N)=O Chemical compound C[C@@]1(CC2)C=CCC1C(CCc1c3)C2c1cc([RnH])c3C(N)=O UFLIUMJUCSZFHG-NZWIDFBWSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55269204P | 2004-03-12 | 2004-03-12 | |
| US56279304P | 2004-04-16 | 2004-04-16 | |
| PCT/US2005/008384 WO2005089256A2 (en) | 2004-03-12 | 2005-03-11 | Antiangiogenic agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007529426A JP2007529426A (ja) | 2007-10-25 |
| JP2007529426A5 true JP2007529426A5 (enExample) | 2008-04-24 |
Family
ID=34994222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007503101A Pending JP2007529426A (ja) | 2004-03-12 | 2005-03-11 | 抗血管新生薬 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US7498322B2 (enExample) |
| EP (1) | EP1756139A4 (enExample) |
| JP (1) | JP2007529426A (enExample) |
| AU (1) | AU2005222934B2 (enExample) |
| CA (1) | CA2558014A1 (enExample) |
| WO (1) | WO2005089256A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6346510B1 (en) | 1995-10-23 | 2002-02-12 | The Children's Medical Center Corporation | Therapeutic antiangiogenic endostatin compositions |
| JP2006526025A (ja) | 2003-05-28 | 2006-11-16 | エントレメッド インコーポレイテッド | 抗血管新生剤 |
| JP2007529426A (ja) | 2004-03-12 | 2007-10-25 | エントレメッド インコーポレイテッド | 抗血管新生薬 |
| US7419972B2 (en) | 2004-07-02 | 2008-09-02 | Schering Ag | 2-substituted estra-1,3,5(10)-trien-17-ones as inhibitors of 17β-hydroxy steroid dehydrogenase type 1 |
| DE102004032674A1 (de) * | 2004-07-02 | 2006-01-26 | Schering Ag | Neue 2-substituierte Estra-1,3,5(10)-trien-17-one als Inhibitoren der 17β-Hydroxysteroiddehydrogenase Typ 1 |
| WO2006058298A2 (en) * | 2004-11-29 | 2006-06-01 | Entremed, Inc. | A method of administering anti-angiogenic agents and a method of treating disease using same |
| GB2430364A (en) * | 2005-09-22 | 2007-03-28 | Carl Ernest Alexander | Soft agar bolus for oral drug delivery |
| US10174070B2 (en) | 2005-09-30 | 2019-01-08 | Endece Llc | 6-substituted estradiol derivatives and methods of use |
| US20070185069A1 (en) * | 2005-11-14 | 2007-08-09 | Plum Stacy M | Anti-angiogenic activity of 2-methoxyestradiol in combination with anti-cancer agents |
| AU2007227256B2 (en) | 2006-03-20 | 2012-10-04 | Entremed, Inc. | Disease modifying anti-arthritic activity of 2-methoxyestradiol |
| ES2397292T3 (es) * | 2007-01-15 | 2013-03-06 | Santen Pharmaceutical Co., Ltd | Nuevo derivado de indol que tiene actividad inhibidora de cinasa I B |
| WO2008094665A1 (en) * | 2007-01-31 | 2008-08-07 | Entremed, Inc. | Method of treating amyloidosis mediated diseases |
| WO2010007972A1 (ja) * | 2008-07-14 | 2010-01-21 | 参天製薬株式会社 | カルバモイル基、ウレイド基及び置換オキシ基を有する新規インドール誘導体 |
| US20100113404A1 (en) * | 2008-10-31 | 2010-05-06 | Theresa Lavallee | Anti-angiogenic activity of 2-methoxyestradiol analogs in combination with anti-cancer agents |
| DE102011083725A1 (de) | 2011-09-29 | 2013-04-04 | Bayer Pharma AG | Estra-1,3,5(10),16-tetraen-3-carboxamid-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln |
| EP2872524B1 (de) | 2012-07-10 | 2016-08-24 | Bayer Pharma Aktiengesellschaft | 3-substituierte estra-1,3,5 (10),16-tetraen-derivate, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln |
| EA201500851A1 (ru) | 2013-02-21 | 2016-02-29 | Байер Фарма Акциенгезельшафт | ЭСТРА-1,3,5(10),16-ТЕТРАЕН-3-КАРБОКСАМИДЫ ДЛЯ ИНГИБИРОВАНИЯ 17β-ГИДРОКСИСТЕРОИД-ДЕГИДРОГЕНАЗЫ (AKR1C3) |
| ES2651442T3 (es) * | 2014-12-30 | 2018-01-26 | Curadis Gmbh | Esteroides C-19 para inhibir la neovascularización |
| CN104557602B (zh) * | 2015-01-07 | 2016-08-17 | 华东师范大学 | 三环二萜衍生物及其制备方法、及其在制备抗肿瘤药物中的应用 |
Family Cites Families (133)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2584271A (en) | 1948-06-19 | 1952-02-05 | Searle & Co | Steroid derivatives and method for producing the same |
| GB857081A (en) | 1956-05-29 | 1960-12-29 | Syntex Sa | Cyclopentanophenanthrene derivatives and process for the production thereof |
| GB857080A (en) | 1956-05-29 | 1960-12-29 | Syntex Sa | Cyclopentanophenanthrene derivatives and process for the production thereof |
| US3166577A (en) | 1956-05-29 | 1965-01-19 | Syntex Corp | 1, 2-dimethyl estrogens and intermediates used in the production thereof |
| US2846453A (en) | 1957-05-28 | 1958-08-05 | Searle & Co | Alpha-ring-acylated estrone derivatives, and corresponding alcohols, their esters, and ethers |
| DE1107664B (de) * | 1959-11-05 | 1961-05-31 | Schering Ag | Verfahren zur Herstellung neuer in 3-Stellung substituierter OEstratriene |
| DE1907330U (de) | 1964-04-13 | 1964-12-23 | Standard Elektrik Lorenz Ag | Maschine zum einfuehren von einlagen in briefumschlaege. |
| US3562260A (en) | 1965-08-23 | 1971-02-09 | Ormonoterapia Richter Spa | 2-carbonyl-estratrienes and method of their preparation |
| US3470879A (en) * | 1966-01-07 | 1969-10-07 | Meiller Research Inc | Orthopedic shoe construction |
| FR1492181A (fr) * | 1966-06-20 | 1967-08-18 | Materiel Telephonique | Bloc pompe-moteur |
| US3470218A (en) | 1966-12-27 | 1969-09-30 | Allied Chem | New 2-substituted estrogenic steroids |
| US3410879A (en) | 1967-04-12 | 1968-11-12 | American Home Prod | Process for preparing gonahexaenes |
| US3492321A (en) | 1968-01-22 | 1970-01-27 | Syntex Corp | Cyclopropenyl estra, -1,3,5(10)-trienes |
| US3496272A (en) | 1968-01-23 | 1970-02-17 | American Home Prod | Ester of 3-(2-propynyloxy)-estradiol |
| GB1502635A (en) | 1974-02-27 | 1978-03-01 | Schering Ag | Process for splitting steroid ethers |
| JPS5265259A (en) | 1975-11-27 | 1977-05-30 | Takeda Chem Ind Ltd | Synthesis of 16beta-alkylestradiol or its 17-esters |
| NL7613248A (nl) | 1976-11-26 | 1978-05-30 | Akzo Nv | Werkwijze voor het bereiden van nieuwe steroid- esters. |
| US4172132A (en) | 1977-07-26 | 1979-10-23 | Schering Corporation | 1,3,5(10),6,8,14-19-Nor-pregnahexaenes, their use as anti-psoriatic agents, and pharmaceutical formulations useful therefor |
| FR2515188A1 (fr) | 1981-10-27 | 1983-04-29 | Roussel Uclaf | Nouveaux derives du 3-amino-pregn-5-ene, leurs sels, procede de preparation, application a titre de medicaments et compositions les renfermant |
| US5001116A (en) | 1982-12-20 | 1991-03-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
| US4994443A (en) | 1982-12-20 | 1991-02-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
| US4552758A (en) | 1983-12-20 | 1985-11-12 | St. Jude Children's Research Hospital | Human use of avian-human reassortants as vaccines for influenza A virus |
| US4522758A (en) | 1983-12-22 | 1985-06-11 | Eli Lilly And Company | Method of preparing 2-fluoro-17β-estradiol |
| US4634705A (en) | 1984-06-06 | 1987-01-06 | Abbott Laboratories | Adrenergic amidines |
| EP0166937B1 (en) | 1984-06-06 | 1991-08-28 | Abbott Laboratories | Adrenergic compounds |
| SU1240038A1 (ru) | 1984-11-23 | 1996-10-27 | Уральский политехнический институт им.С.М.Кирова | 3-оксиэстра-1,3,5-триен-17-гидразон, обладающий гормональной и противоопухолевой активностью |
| EP0243449A1 (en) | 1985-10-18 | 1987-11-04 | The Upjohn Company | Cyclic hydrocarbons with an aminoalkyl sidechain |
| JPH0446120Y2 (enExample) | 1985-12-03 | 1992-10-29 | ||
| US4743597A (en) | 1986-01-27 | 1988-05-10 | Javitt Norman B | Composition comprising an oxygenated cholesterol and use thereof for topical treatment of diseases |
| JPS62135472U (enExample) | 1986-02-20 | 1987-08-26 | ||
| JP2544136B2 (ja) | 1986-05-23 | 1996-10-16 | 第一製薬株式会社 | 硫酸化多糖体ｄｓ４１５２を含有する血管新生抑制剤及び抗腫瘍剤 |
| DE3625315A1 (de) | 1986-07-25 | 1988-01-28 | Schering Ag | 11ss-(4-isopropenylphenyl)-estra-4,9-diene, deren herstellung und diese enthaltende pharmazeutische praeparate |
| JP2517561B2 (ja) | 1986-10-03 | 1996-07-24 | 新技術事業団 | カテコ−ルエストロゲンのイムノアツセイキツド |
| US5352664A (en) | 1986-10-31 | 1994-10-04 | Board Of Regents, The University Of Texas System | Thrombin derived polypeptides; compositions and methods for use |
| DE3872234T2 (de) | 1987-04-16 | 1993-01-07 | Upjohn Co | Zyklische kohlenwasserstoffe mit aminoalkyl-seitenkette. |
| US4808402A (en) | 1987-05-29 | 1989-02-28 | Northwestern University | Method and compositions for modulating neovascularization |
| US5135919A (en) | 1988-01-19 | 1992-08-04 | Children's Medical Center Corporation | Method and a pharmaceutical composition for the inhibition of angiogenesis |
| EP0477195A1 (en) | 1989-06-16 | 1992-04-01 | The Upjohn Company | Suramin type compounds and angiostatic steroids to inhibit angiogenesis |
| US5166149A (en) | 1989-09-08 | 1992-11-24 | Chemex Pharmaceuticals, Inc. | Methotrexate compositions and methods of treatment using same |
| IT1247827B (it) | 1991-02-05 | 1995-01-02 | Erba Carlo Spa | Benzoil carbinolo e suoi esteri, utili come inibitori dell'angiogenesi |
| WO1993003729A1 (en) | 1991-08-12 | 1993-03-04 | Research Corporation Technologies, Inc. | N-substituted phenoxazines for treating multidrug resistant cancer cells |
| US6011024A (en) | 1991-08-28 | 2000-01-04 | Imperial College Of Science Technology & Medicine | Steroid sulphatase inhibitors |
| EP0619738B1 (en) | 1991-12-02 | 2003-07-09 | Millennium Pharmaceuticals, Inc. | Inhibitory immunoglobulin polypeptides to human pdgf beta receptor |
| GB9207437D0 (en) | 1992-04-03 | 1992-05-20 | Orion Yhtymae Oy | Topical administration of toremifene and its metabolites |
| DE4235657A1 (de) | 1992-10-22 | 1994-06-23 | Schering Ag | Verfahren zum Alkylieren von Östronderivaten |
| KR960700045A (ko) | 1993-01-11 | 1996-01-19 | 가자마 하치자에몽 | 혈관신생 저해제 및 신규 화합물 |
| US5629327A (en) | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
| DE69433013T2 (de) | 1993-05-27 | 2004-06-03 | Entremed, Inc. | Zubereitungen und verfahren für die behandlung von krebs und hyperproliferierenden krankheiten |
| US5643900A (en) | 1993-07-02 | 1997-07-01 | Fotsis; Theodore | Method for treatment of pathological conditions associated with angiogenesis and preparation therefor |
| US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
| US20040214807A1 (en) | 1993-08-06 | 2004-10-28 | D'amato Robert J. | Estrogenic compounds as anti-mitotic agents |
| US6908910B2 (en) | 1993-08-06 | 2005-06-21 | The Children's Medical Center Corporation | Estrogenic compounds as anti-mitotic agents |
| US5504074A (en) | 1993-08-06 | 1996-04-02 | Children's Medical Center Corporation | Estrogenic compounds as anti-angiogenic agents |
| DE69434279T2 (de) | 1993-12-09 | 2006-04-06 | Centro De Inmunologia Molecular | Impfstoff, der einen menschlichen autologenen epidermalen Wachstumsfaktor enthält und dessen Verwendung |
| US5646136A (en) | 1994-01-04 | 1997-07-08 | Duke University | Methods of inhibiting angiogenesis and tumor growth, and treating ophthalmologic conditions with angiostatic and therapeutic steroids |
| US5639725A (en) | 1994-04-26 | 1997-06-17 | Children's Hospital Medical Center Corp. | Angiostatin protein |
| US5837682A (en) | 1996-03-08 | 1998-11-17 | The Children's Medical Center Corporation | Angiostatin fragments and method of use |
| CN1636594B (zh) | 1994-04-26 | 2012-08-29 | 儿童医学中心公司 | 血管生成抑制素和用于抑制血管生成的方法 |
| US5521168A (en) | 1994-10-13 | 1996-05-28 | Alcon Laboratories, Inc. | Estrogen metabolites for lowering intraocular pressure |
| US5861372A (en) | 1996-02-22 | 1999-01-19 | The Children's Medical Center Corporation | Aggregate angiostatin and method of use |
| US5854205A (en) | 1995-10-23 | 1998-12-29 | The Children's Medical Center Corporation | Therapeutic antiangiogenic compositions and methods |
| US6346510B1 (en) | 1995-10-23 | 2002-02-12 | The Children's Medical Center Corporation | Therapeutic antiangiogenic endostatin compositions |
| US5854221A (en) | 1996-12-12 | 1998-12-29 | The Children's Medical Center Corporation | Endothelial cell proliferation inhibitor and method of use |
| EP0888310B1 (en) | 1996-03-15 | 2005-09-07 | AstraZeneca AB | Cinnoline derivatives and use as medicine |
| US5962445A (en) | 1996-05-09 | 1999-10-05 | Amrad Operations Pty Ltd. | Treatment of asthma and airway diseases |
| JPH09316000A (ja) | 1996-05-31 | 1997-12-09 | Toagosei Co Ltd | 血管新生抑制用ワクチン |
| US5958892A (en) | 1996-07-30 | 1999-09-28 | Board Of Regents, The University Of Texas System | 2-methoxyestradiol-induced apoptosis in cancer cells |
| US5763432A (en) | 1997-01-29 | 1998-06-09 | Sri International | Steriod inhibitors of estrone sulfatase and associated pharmaceutical compositions and methods of use |
| US6136992A (en) | 1997-03-13 | 2000-10-24 | The United States Of America As Represented By The Department Of Health And Human Services | 2-alkoxy estradiols and derivatives thereof |
| US6051726A (en) | 1997-03-13 | 2000-04-18 | Pharm-Eco Laboratories, Inc. | Synthesis of 2-alkoxyestradiols |
| CA2208916A1 (en) | 1997-07-03 | 1999-01-03 | Hyal Pharmaceutical Corporation | Promotion of wound healing utilizing steroids having reduced deterioroussystemic side effects typical of glucocorticoids, mineralocorticoids andsex steroids |
| US6011023A (en) | 1997-08-27 | 2000-01-04 | Alcon Laboratories, Inc. | Angiostatic steroids |
| US20020002294A1 (en) | 1997-09-24 | 2002-01-03 | D' Amato Robert J. | Estrogenic compounds as antiangiogenic agents |
| US6576660B1 (en) | 1997-10-31 | 2003-06-10 | Arch Development Corporation | Methods and compositions for regulation of 5-α-reductase activity |
| US6046186A (en) | 1997-12-24 | 2000-04-04 | Sri International | Estrone sulfamate inhibitors of estrone sulfatase, and associated pharmaceutical compositions and methods of use |
| US6054446A (en) | 1997-12-24 | 2000-04-25 | Sri International | Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use |
| JPH11209322A (ja) | 1998-01-27 | 1999-08-03 | Kao Corp | イソバニリルアルコール誘導体 |
| AU2994599A (en) | 1998-03-06 | 1999-09-20 | Imclone Systems Incorporated | Active immunization against angiogenesis-associated antigens |
| KR20010043558A (ko) | 1998-05-13 | 2001-05-25 | 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 | 감수분열 조절 화합물 |
| US6413513B1 (en) | 1998-05-22 | 2002-07-02 | Entremed, Inc. | Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers |
| AR021757A1 (es) | 1998-08-07 | 2002-08-07 | Endorech Inc | Metodo para inhibir la conversion de 4-androstan-3,17-diona en testosterona o de 3alfa-androstan-3,17-diona en dihidrotestosterona, inhibir la actividadde la 3alfa-hidroxiesteroide deshidrogenasa de tipo 3 humana, para determinar la eficacia de un inhibidor putativo de la conversion de 4-androsten-3 |
| WO2000009101A2 (en) | 1998-08-11 | 2000-02-24 | Entremed, Inc. | Use of estrogenic compounds as anti-fungal agents |
| WO2000010552A2 (en) | 1998-08-24 | 2000-03-02 | Global Vascular Concepts, Inc. | Use of anti-angiogenic agents for inhibiting vessel wall injury |
| US6284789B1 (en) | 1998-09-04 | 2001-09-04 | The Research Foundation Of State University Of New York | Formation and composition of new optically active compounds |
| CA2348234A1 (en) | 1998-10-29 | 2000-05-11 | Chunjian Liu | Compounds derived from an amine nucleus that are inhibitors of impdh enzyme |
| NZ515061A (en) | 1999-04-30 | 2004-04-30 | Sterix Ltd | Use of a cyclic compound in cell cycling |
| US20060025393A1 (en) | 1999-04-30 | 2006-02-02 | Shutsung Liao | Steroid derivatives |
| GB9910934D0 (en) | 1999-05-11 | 1999-07-14 | Res Inst Medicine Chem | Chemical compounds |
| US6730665B1 (en) | 1999-05-12 | 2004-05-04 | Mayo Foundation For Medical Education And Research | Treatment of bone cancer |
| US7087592B1 (en) | 1999-08-23 | 2006-08-08 | Entre Med, Inc. | Compositions comprising purified 2-methoxyestradiol and methods of producing same |
| US6358940B1 (en) | 1999-09-07 | 2002-03-19 | Rutgers, The State University | Modified 2-Alkoxyestradiol derivatives with prolonged pharmacological activity |
| AUPQ342599A0 (en) | 1999-10-14 | 1999-11-04 | University Of Melbourne, The | Conjugates and uses thereof |
| WO2001052883A1 (en) | 2000-01-20 | 2001-07-26 | Amgen Inc. | Inhibitors of protease-activated receptor-2 (par-2) as novel asthma therapeutics |
| US20020035098A1 (en) | 2000-03-17 | 2002-03-21 | Oncology Sciences Corporation | Agents and methods for the prevention of initial onset and recurrence of existing cancers |
| US20020068724A1 (en) | 2000-03-17 | 2002-06-06 | Oncology Sciences Corporation | Method and composition of novel compounds for the therapy and targeting of the primary modalities of cancer cell proliferation and homeostasis |
| US20030027803A1 (en) | 2000-03-17 | 2003-02-06 | Oncology Sciences Corporation | Method and composition for inhibiting the incidence and proliferation of nervous system and brain cancer cells |
| EP1604024A4 (en) | 2000-04-06 | 2008-04-23 | Wayne P Franco | METHODS OF USING GROWTH FACTORS FOR TREATING CARDIOPATHY |
| EP1284272A4 (en) | 2000-04-24 | 2003-09-10 | Kyowa Hakko Kogyo Kk | ESTRA-1,3,5 (10) -TRIENE DERIVATIVES |
| ES2247102T3 (es) | 2000-05-11 | 2006-03-01 | Research Institute For Medicine And Chemistry Inc. | Derivados de cola-1,3,5(10)-trieno y pregna-1,3,5(10)-trieno 2-sustituidos y su actividad biologica. |
| US6995278B2 (en) | 2000-08-18 | 2006-02-07 | Entre Med, Inc. | Antiangiogenic agents |
| US7135581B2 (en) | 2000-08-18 | 2006-11-14 | Entremed, Inc. | Antiangiogenic agents |
| US20050192258A1 (en) | 2000-08-18 | 2005-09-01 | Agoston Gregory E. | Antiangiogenic agents |
| WO2002015910A1 (en) | 2000-08-18 | 2002-02-28 | Sterix Limited | 2-substituted estradiol derivative for inhibiting superoxid dismutase |
| WO2002062347A1 (en) | 2001-02-05 | 2002-08-15 | Oncology Sciences Corporation | Method and composition of novel compounds for the therapy and targeting of the primary modalities of cancer cell proliferation and homeostasis |
| US20040116397A1 (en) | 2001-03-19 | 2004-06-17 | Slaga Tom J | Agents and methods for the prevention of initial onset of cancers, the treatment of cancers, and the recurrence of existing cancers |
| US8048869B2 (en) | 2001-05-18 | 2011-11-01 | Pantarhei Bioscience B.V. | Pharmaceutical composition for use in hormone replacement therapy |
| EP1260225A1 (en) | 2001-05-18 | 2002-11-27 | Pantarhei Bioscience B.V. | A pharmaceutical composition for use in hormone replacement therapy |
| US6593321B2 (en) | 2001-06-11 | 2003-07-15 | Southwest Foundation For Biomedical Research | 2-alkoxyestradiol analogs with antiproliferative and antimitotic activity |
| US6448419B1 (en) | 2001-08-07 | 2002-09-10 | Tetrionics, Inc. | Synthesis of 2-hydroxyestradiol derivatives |
| AU2002331618B2 (en) | 2001-08-17 | 2007-11-01 | University Of Pittsburgh | Administration of estradiol metabolites for the treatment or prevention of obesity, metabolic syndrome, diabetes, and vascular and renal disorders |
| CA2467222C (en) | 2001-11-15 | 2010-06-08 | Herman Jan Tijmen Coelingh Bennink | Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy |
| US20030175961A1 (en) | 2002-02-26 | 2003-09-18 | Herron G. Scott | Immortal micorvascular endothelial cells and uses thereof |
| WO2003075917A1 (en) | 2002-03-08 | 2003-09-18 | Signal Pharmaceuticals, Inc. | Combination therapy for treating, preventing or managing proliferative disorders and cancers |
| CA2479665C (en) | 2002-03-20 | 2011-08-30 | Elan Pharma International Ltd. | Nanoparticulate compositions of angiogenesis inhibitors |
| US20040082558A1 (en) | 2002-08-02 | 2004-04-29 | Tofovic Stevan P. | Administration of estradiol metabolites for inhibition of drug-induced nephrotoxicity |
| AU2003298873B2 (en) | 2002-12-06 | 2011-09-01 | Millennium Pharmaceuticals, Inc. | Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy |
| US20040121968A1 (en) | 2002-12-23 | 2004-06-24 | Alexander Ljubimov | Antiangiogenesis by inhibiting protein kinase CK2 activity |
| DE10307104A1 (de) * | 2003-02-19 | 2004-09-23 | Schering Ag | Antitumor wirksame 2-substituierte Estra-1,3,5(10)-trien-3-yl sulfamate |
| CA2516452A1 (en) | 2003-02-20 | 2004-09-02 | University Of Pittsburgh | Estradiol metabolites for the treatment of pulmonary hypertension |
| US7687486B2 (en) | 2003-04-29 | 2010-03-30 | Florida Agricultural & Mechanical University | Selective estrogen receptor modulators |
| US20050148565A1 (en) | 2003-04-29 | 2005-07-07 | Cooperwood John S. | Use of aminoalkyloxy derivatives of 1,3,5(10)-Estratrien and -Estratetraene steroids in the treatment of breast cancer |
| US20070275935A1 (en) | 2003-05-13 | 2007-11-29 | Stewart Alastair G | Estratriene Derivatives |
| JP2006526025A (ja) | 2003-05-28 | 2006-11-16 | エントレメッド インコーポレイテッド | 抗血管新生剤 |
| US20050032766A1 (en) | 2003-08-05 | 2005-02-10 | Green Shawn J. | Use of estrogenic compounds as anti-fungal agents |
| AU2004294950A1 (en) | 2003-11-26 | 2005-06-16 | Entelos, Inc. | Treatment of rheumatoid arthritis with Hypoxia-Inducible Factor 1alpha antagonists |
| JP2007526322A (ja) | 2004-03-02 | 2007-09-13 | マサチューセッツ インスティテュート オブ テクノロジー | ナノセル薬物送達系 |
| US7495026B2 (en) | 2004-03-10 | 2009-02-24 | The University Of North Carolina At Chapel Hill | Neo-tanshinlactone and analogs as potent and selective anti-breast cancer agents |
| US20070004689A1 (en) | 2004-03-12 | 2007-01-04 | Agoston Gregory E | Antiangiogenic agents |
| JP2007529426A (ja) | 2004-03-12 | 2007-10-25 | エントレメッド インコーポレイテッド | 抗血管新生薬 |
| JP2008510726A (ja) | 2004-08-20 | 2008-04-10 | エントレメッド インコーポレイテッド | プロテイナーゼ活性化受容体アンタゴニストを含む組成物および方法 |
| US7608594B2 (en) | 2004-11-03 | 2009-10-27 | University Of Kansas | Novobiocin analogues as anticancer agents |
| WO2006058298A2 (en) | 2004-11-29 | 2006-06-01 | Entremed, Inc. | A method of administering anti-angiogenic agents and a method of treating disease using same |
| KR20070099031A (ko) | 2005-01-25 | 2007-10-08 | 셀진 코포레이션 | 4-아미노-2-(3-메틸-2,6-디옥소피페리딘-3-일)-이소인돌-1,3-디온을 사용한 방법 및 조성물 |
-
2005
- 2005-03-11 JP JP2007503101A patent/JP2007529426A/ja active Pending
- 2005-03-11 WO PCT/US2005/008384 patent/WO2005089256A2/en not_active Ceased
- 2005-03-11 US US11/077,977 patent/US7498322B2/en not_active Expired - Fee Related
- 2005-03-11 CA CA002558014A patent/CA2558014A1/en not_active Abandoned
- 2005-03-11 EP EP05736385A patent/EP1756139A4/en not_active Withdrawn
- 2005-03-11 AU AU2005222934A patent/AU2005222934B2/en not_active Ceased
-
2008
- 2008-12-22 US US12/341,068 patent/US8158612B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007529426A5 (enExample) | ||
| JP2006526025A5 (enExample) | ||
| CN101707888B (zh) | 用7-乙基-10-羟基喜树碱的多臂聚合物缀合物治疗非霍奇金氏淋巴瘤 | |
| US7112602B2 (en) | Methods of treating undesired angiogenesis with 2-methyl-EM-138 | |
| US20070105903A1 (en) | Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs | |
| AU2002311985B2 (en) | Methods for inhibiting angiogenesis | |
| JP2004514663A5 (enExample) | ||
| CA2440037A1 (en) | Benzimidazole derivatives for modulating the rage receptor | |
| JP2010524963A5 (enExample) | ||
| CA2361364A1 (en) | Dalda analogs and their use | |
| AU2002311985A1 (en) | Methods for inhibiting angiogenesis | |
| JP7764041B2 (ja) | 脳腫瘍における改善された血液脳関門浸透性及び滞留性を備えた、スケーラブルなチロインテグリンアンタゴニストの組成物 | |
| JP2022548424A (ja) | ポリエチレングリコール複合薬、ならびにその調製方法およびその使用 | |
| JP2023505509A (ja) | ポリエチレングリコール複合薬、ならびにその調製方法およびその使用 | |
| JP2006521407A5 (enExample) | ||
| JP2002514578A5 (enExample) | ||
| EP1091726A2 (en) | Analogs of 2-phthalimidinoglutaric acid and their use as inhibitors of angiogenesis | |
| JP2013525290A5 (enExample) | ||
| JP4149172B2 (ja) | インテグリンと受容体との結合を阻害するカルボン酸誘導体 | |
| US20080293648A1 (en) | Compositions and Methods for Cancer Treatment | |
| KR102138415B1 (ko) | 신규 peg 유도체 | |
| CN113164474B (zh) | 维奈托克的水溶性高分子衍生物 | |
| JP2008521822A (ja) | 抗血管形成剤を投与する方法、およびそれを用いて疾病を治療する方法 | |
| US20160143914A1 (en) | Nanoparticles for Encapsulation and Delivery of Bioactive Compounds and Compositions Thereof | |
| CA2431761A1 (en) | Novel 2,3-benzodiazepine derivatives and pharmaceutical compositions containing the same as the active ingredient |